The MEIP chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the MEIP chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The MEIP stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View MEIP Detailed Price Forecast - CNN Money||View MEIP Detailed Summary - Google Finance|
|View MEIP Detailed Summary - Yahoo! Finance||View MEIP Stock Research & Analysis - Zacks.com|
|View MEIP Trends & Analysis - Trade-Ideas||View MEIP Major Holders - Barrons|
|View MEIP Call Transcripts - NASDAQ||View MEIP Breaking News & Analysis - Seeking Alpha|
|View MEIP Annual Report - CompanySpotlight.com||View MEIP OTC Short Report - OTCShortReport.com|
|View MEIP Fundamentals - TradeKing||View MEIP SEC Filings - Bar Chart|
|View Historical Prices for MEIP - The WSJ||View Performance/Total Return for MEIP - Morningstar|
|View the Analyst Estimates for MEIP - MarketWatch||View the Earnings History for MEIP - CNBC|
|View the MEIP Earnings - StockMarketWatch||View MEIP Buy or Sell Recommendations - MacroAxis|
|View the MEIP Bullish Patterns - American Bulls||View MEIP Short Pain Metrics - ShortPainBot.com|
|View MEIP Stock Mentions - StockTwits||View MEIP Stock Mentions - PennyStockTweets|
|View MEIP Stock Mentions - Twitter||View MEIP Investment Forum News - Investor Hub|
|View MEIP Stock Mentions - Yahoo! Message Board||View MEIP Stock Mentions - Seeking Alpha|
|View Insider Transactions for MEIP - SECform4.com||View Insider Transactions for MEIP - Insider Cow|
|View MEIP Major Holdings Summary - CNBC||View Insider Disclosure for MEIP - OTC Markets|
|View Insider Transactions for MEIP - Yahoo! Finance||View Institutional Holdings for MEIP - NASDAQ|
|View MEIP Stock Insight & Charts - FinViz.com||View MEIP Investment Charts - StockCharts.com|
|View MEIP Stock Overview & Charts - BarChart||View MEIP User Generated Charts - Trading View|
MEI Pharma Presents Clinical Data on ME-401 at the European Hematology Association Congress
Posted on Friday June 15, 2018
SAN DIEGO, June 15, 2018 /PRNewswire/ -- MEI Pharma, Inc. (MEIP) a pharmaceutical company focused on leveraging its extensive development and oncology expertise to identify and advance new therapies for cancer, today announced that results from a Phase 1b study of ME-401 in patients with relapsed or refractory follicular lymphoma (FL), chronic lymphocytic lymphoma (CLL) and small lymphocytic lymphoma (SLL) are being presented during a poster presentation today, Friday, June 15, 2018 at the 23rd Congress of the European Hematology Association (EHA) in Stockholm, Sweden. Complete data results on the Phase 1b study were previously announced at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago in June 2018.
MEI Pharma, Partnerships, Well-Funded Clinical Programs and Promising Clinical Data Driving Oncology Research
Posted on Monday June 11, 2018
Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on MEI Pharma (MEIP), a San Diego-based oncology drug development company with a pipeline of three clinical-stage drug candidates and oncology drug development experience. Followed by promising partnerships, well-funded clinical programs, and most recently, promising data at ASCO for ME-401 and the potential for having a best-in-class P13K Delta oral inhibitor. On June 4th, the company announced that data presented at ASCO 2018 from a Phase 1b study of ME-401, demonstrated a 90% objective response rate in patients with relapsed or refractory follicular lymphoma (FL), chronic lymphocytic lymphoma (CLL) and small lymphocytic lymphoma (SLL).
MEI Pharma Presents Phase 1b Clinical Data for ME-401 in Patients with Indolent B-Cell Malignancies at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
Posted on Monday June 04, 2018
-- 90% Objective Response Rate Observed in Patients with Indolent B-Cell Malignancies -- SAN DIEGO , June 4, 2018 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP) a pharmaceutical company focused on leveraging ...
SAN DIEGO, June 4, 2018 /PRNewswire/ -- MEI Pharma, Inc. (MEIP), a pharmaceutical company focused on leveraging its extensive development and oncology expertise to identify and advance new therapies for cancer, today announced that data presented at ASCO 2018 from an investigator-initiated study of ME-344 in patients with HER2 negative breast cancer demonstrate evidence of inhibition of tumor proliferation as measured by Ki-67 reductions.